World's Best Scientists 2026 revealed!
Jan H.M. Schellens

Jan H.M. Schellens

Award Badge
Medicine
Netherlands
2023

D-Index & Metrics

Medicine

D-Index
131
Citations
71769
World Ranking
2376
National Ranking
90

Jan H.M. Schellens publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jan H.M. Schellens sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 964 publications — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jan H.M. Schellens D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jan H.M. Schellens sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 131 D-Index — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Netherlands Leader Award

Overview

Jan H.M. Schellens is affiliated with Utrecht University in the Netherlands and has an extensive research profile focused primarily on medicine and biochemistry, genetics, and molecular biology. Their work spans multiple subfields, with significant contributions to oncology, molecular biology, pulmonary and respiratory medicine, cancer research, and radiology, nuclear medicine, and imaging.

Their main research topics include colorectal cancer treatments and studies, lung cancer treatments and mutations, signaling pathways such as PI3K/AKT/mTOR in cancer, cancer genomics and diagnostics, melanoma and MAPK pathways, PARP inhibition in cancer therapy, and cancer treatment and pharmacology.

Jan H.M. Schellens has contributed to a number of recent papers, highlighting involvement in clinical cancer research and therapeutic trials. Notable publications include:

  • Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial, 2020, The Lancet Oncology
  • Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study, 2022, Annals of Oncology
  • Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial, 2023, Nature Medicine
  • Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study, 2020, Cancer
  • A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours, 2020, British Journal of Cancer

Frequent co-authors who have collaborated with Jan H.M. Schellens include:

  • Jos H. Beijnen
  • Hilde Rosing
  • Alwin D. R. Huitema
  • Jonathan E. Knikman
  • Annemieke Cats

Publications featuring Jan H.M. Schellens frequently appear in several distinguished scientific journals such as Annals of Oncology, British Journal of Cancer, Clinical Pharmacology & Therapeutics, Clinical Cancer Research, and Cancer Research.

Best Publications

  • Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

    Peter C Fong;David S Boss;Timothy A Yap;Andrew Tutt

  • Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

    M Maliepaard;G L Scheffer;I F Faneyte;M A van Gastelen

  • Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

    Scott Kopetz;Axel Grothey;Rona Yaeger;Eric Van Cutsem

  • A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

    Jeany M. Rademaker-Lakhai;Desiree van den Bongard;Dick Pluim;Jos H. Beijnen

  • Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

    Peter C. Fong;Timothy A. Yap;David S. Boss;Craig P. Carden

  • Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

    John D Allen;Arnold van Loevezijn;Jeany M Lakhai;Martin van der Valk

  • Photodynamic Therapy in Oncology

    Martijn Triesscheijn;Paul Baas;Jan H. M. Schellens;Jan H. M. Schellens;Fiona A. Stewart

  • Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan

    Johan W. Jonker;Johan W. Smit;Remco F. Brinkhuis;Marc Maliepaard

  • Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer

    Vivek Subbiah;Robert J. Kreitman;Zev A. Wainberg;Jae Yong Cho

  • An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons.

    Esther F.A Brandon;Christiaan D Raap;Irma Meijerman;Jos H Beijnen;Jos H Beijnen

  • Clinical pharmacokinetics of therapeutic monoclonal antibodies.

    Ron J. Keizer;Alwin D. R. Huitema;Jan H. M. Schellens;Jan H. M. Schellens;Jos H. Beijnen;Jos H. Beijnen

  • Overexpression of the BCRP/MXR/ABCP Gene in a Topotecan-selected Ovarian Tumor Cell Line

    Maliepaard M;van Gastelen Ma;de Jong La;Pluim D

  • Approaching tumour therapy beyond platinum drugs : status of the art and perspectives of ruthenium drug candidates.

    A. Bergamo;C. Gaiddon;J.H.M. Schellens;J.H. Beijnen

  • Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

    Ursula Amstutz;Linda M. Henricks;Steven M. Offer;Julia Barbarino

  • The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients

    Pauline Breedveld;Dick Pluim;Greta Cipriani;Peter Wielinga

  • Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer

    Ryan B. Corcoran;Thierry Andre;Chloe E. Atreya;Jan H.M. Schellens

  • Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

    Suzanne Leijen;Sjaak A. Burgers;Paul Baas;Dick Pluim

  • Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.

    Pauline Breedveld;Jos H. Beijnen;Jos H. Beijnen;Jan H.M. Schellens;Jan H.M. Schellens

  • Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

    K.M. Heinhuis;W. Ros;M. Kok;N. Steeghs

  • Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.

    Vivek Subbiah;Ulrik Lassen;Elena Élez;Antoine Italiano

Frequent Co-Authors

Jos H. Beijnen
Jos H. Beijnen Utrecht University
Hilde Rosing
Hilde Rosing Antoni van Leeuwenhoek Hospital
Emile E. Voest
Emile E. Voest Antoni van Leeuwenhoek Hospital
Alfred H. Schinkel
Alfred H. Schinkel Antoni van Leeuwenhoek Hospital
Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Stan B. Kaye
Stan B. Kaye Royal Marsden NHS Foundation Trust
Jaap Verweij
Jaap Verweij Erasmus University Rotterdam
Ron H.J. Mathijssen
Ron H.J. Mathijssen Erasmus University Rotterdam
Ahmad Awada
Ahmad Awada Université Libre de Bruxelles
Henk-Jan Guchelaar
Henk-Jan Guchelaar Leiden University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative routes within the medical field can open doors to rewarding careers and specialized expertise. For those interested in healthcare administration or working behind the scenes, obtaining the cheapest medical coding certification online is a smart way to gain in-demand skills without a significant financial burden.

If direct patient care is your passion, you might consider one of the most affordable online nurse practitioner programs. These programs allow nurses to expand their roles and provide higher levels of care. Affordable options are also available for those seeking advanced nursing degrees, with the cheapest online msn programs offering flexible pathways to leadership or specialized positions.

For those aiming for top-tier roles in research, education, or advanced clinical practice, pursuing an online nursing doctorate can be a significant step forward. Each of these pathways offers scalable opportunities for growth and advancement within the dynamic healthcare sector.

Best Scientists Citing Jan H.M. Schellens

Trending Scientists

Recently Published Articles